Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) on Thursday released topline results from an interim analysis of a Phase 3 trial indicating that the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, is more effective in preventing HIV infection in women compared to its existing daily pill, Truvada.
Gilead said that there were zero cases of HIV infection among women who were treated with lenacapavir. More detailed data will be presented at a later date.
Truvada, a combination of tenofovir and emtricitabine, can treat HIV and is also used in a prevention regimen known as pre-exposure prophylaxis (PrEP).
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Biophytis and Asian consortium to fund first Phase 3 trial in sarcopenia
Aptamer Group secures GBP112,000 contract with top 10 global pharmaceutical company
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
Jubilant HollisterStier's Washington facility launches new high-speed isolator based Line
Assembly Biosciences reports positive interim Phase 1b data for herpes treatment candidate ABI-5366
Dubai Culture and Zayed University Invite Global Creatives to Participate in ISEA2026
VolitionRx proposes underwritten public offering of common stock and common stock warrants
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
WuXi Biologics recognised with MSCI AAA ESG rating for third consecutive year